Want to see HK:1530 full AI Analyst Report?
1530 Stock Chart & Stats
HK$17.14
HK$0.34(1.98%)
At close: 4:00 PM EDT
HK$17.14
HK$0.34(1.98%)
Day’s Range― - ―
52-Week RangeHK$14.81 - HK$36.80
Previous CloseN/A
Volume13.82M
Average Volume (3M)31.12M
Market Cap
HK$44.50B
Enterprise ValueHK$44.46K
Total Cash (Recent Filing)HK$19.73B
Total Debt (Recent Filing)HK$2.62B
Price to Earnings (P/E)4.4
Beta0.86
Next Earnings
Aug 20, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)3.41
Shares Outstanding2,538,239,500
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.53Price Target Upside72.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.01
Revenue Forecast (FY)HK$9.66B
Bulls Say, Bears Say
Bulls Say
2025 Revenue And Profitability Step-upThe large 2025 revenue surge and exceptionally high margins indicate meaningful scale and commercial traction in core biologics. Durable benefits include stronger internal funding for R&D and commercialization, improved unit economics across the portfolio, and enhanced ability to defend pricing in China’s hospital channels.
Robust Free Cash Flow GenerationNear-parity of free cash flow with net income in 2025 shows high earnings quality and self-funding capacity. Sustained FCF supports durable priorities—R&D, manufacturing scale-up, dividend policy or de-risking through debt reduction—reducing reliance on external capital over the medium term.
Conservative Leverage And Stronger Balance SheetMaterial deleveraging improves financial resilience and lowers refinancing risk, providing strategic optionality for M&A or capex. A stronger balance sheet supports sustained investment in biologics manufacturing and commercialization while cushioning reimbursement or pricing shocks in China.
Bears Say
Historical Volatility In FundamentalsPrior multi-year swings in revenue, margins and returns suggest the 2025 outperformance may reflect lumpy events or timing differences rather than structural improvement. That variability weakens earnings predictability, complicates long-term capital allocation and raises execution risk for sustaining 2025 levels.
2025 Margins Look Atypically HighExtremely elevated gross and net margins in 2025 may be driven by one-offs, mix shifts, or temporary pricing advantages. Given China's reimbursement and centralized procurement dynamics, margins could normalize, which would materially reduce free cash flow and strain reinvestment plans if not supported by durable product-level economics.
Prior Years' Weak Cash ConversionWorking-capital and timing volatility in recent years highlights a recurring operational cash risk: receivable or inventory swings can convert profit into weak cash under stress. This reduces margin of safety for sustained investment and could force external financing if cash conversion worsens during growth or market pressure.
3SBio News
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$14.81 and its highest was HK$36.80 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is HK$44.50B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Aug 20, 2026 which is in 4 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Mar 30, 2026. The company reported HK$3.381 earnings per share for the quarter, missing the consensus estimate of HK$4.201 by -HK$0.82.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 1.43%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.74.
How many shares outstanding does 3SBio have?
3SBio has 2,538,239,500 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$3.381 in its last earnings report, missing expectations of HK$4.201. Following the earnings report the stock price went up 1.248%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
456.34%
12-Months-Change
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
56.38%
Trailing 12-Months
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
1530 Stock 12 Month Forecast
Average Price Target
HK$29.53
▲(72.31% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―